In:
International Journal of Cancer, Wiley, Vol. 150, No. 6 ( 2022-03-15), p. 903-915
Abstract:
The childhood malignancy neuroblastoma belongs to the group of embryonal tumors and originates from progenitor cells of the sympathoadrenal lineage. Treatment options for children with high‐risk and relapsed disease are still very limited. In recent years, an ever‐growing molecular diversity was identified using (epi)‐genetic profiling of neuroblastoma tumors, indicating that molecularly targeted therapies could be a promising therapeutic option. In this review article, we summarize the various molecular subtypes and genetic events associated with neuroblastoma and describe recent advances in targeted therapies. We lay a strong emphasis on the importance of telomere maintenance mechanisms for understanding tumor progression and risk classification of neuroblastoma.
Type of Medium:
Online Resource
ISSN:
0020-7136
,
1097-0215
Language:
English
Publisher:
Wiley
Publication Date:
2022
detail.hit.zdb_id:
218257-9
detail.hit.zdb_id:
1474822-8